Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Journal of the European Academy of Dermatology and Venereology : JEADV|April 24, 2023
Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trialNina Magnolo, Thomas Jaenicke, Athanasios Tsianakas, et al.Paediatric Drugs|June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Külli Kingo, Vivian Laquer, et al.Dermatology and Therapy|December 16, 2021
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSOKristian Reich, Bernhard Korge, Nina Magnolo, et al.Journal of the American Academy of Dermatology|September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Külli Kingo, Vivian Laquer, et al.Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.American Journal of Clinical Dermatology|January 14, 2026
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)Christopher G Bunick, Nina Magnolo, Angela Moore, et al.Paediatric Drugs|August 28, 2025
Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label TrialKulli Kingo, Philemon Papanastasiou, Stefan Beissert, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2025
Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial resultsAndrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, et al.The British Journal of Dermatology|October 21, 2024
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areataMelissa Piliang, Jennifer Soung, Brett King, et al.The Journal of Dermatological Treatment|May 2, 2024
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up studyNina Magnolo, Michael C Cameron, Mona Shahriari, et al.Pageof 4